BREAKING NEWS
The Warriors season is over after a heartbreaking 24-36 loss to the Tigers. ... Read more
Close

Access widened to funded medicines

Last updated 05:00 13/11/2012

Relevant offers

Politics

Stacey Kirk: Long knives being sharpened, but can Helen Clark stay clear of the blades? Below the Beltway: The week in politics Jo Moir: The Maori King has nailed his colours to the mast by shunning Labour Key washes hands of soap 'joke' but has he learned his lesson? PM on prison rape joke: 'It's nothing to do with me' Auckland mayoral hopeful Phil Goff: Limit immigration to fix housing crisis Nick Smith is 'Milllion-dollar Minister' as average Auckland house passes $1m mark Jonathan Milne: There's only one answer to the housing bubble – gently deflate it Oscar Kightley: 'Unfairness at work continues, thanks to one u-turn' Jacinda v David: Put kids at the centre of the school funding debate

Pharmac has spent more than $21.5 million on new drugs and widening access to publicly funded medicines in the past year.

Blood thinning drug Pradaxa, also known as dabigatran, was the most expensive new drug to be funded, with an estimated annual cost of $16 million.

Two new drugs targeting specific types of breast and kidney cancer were also added to the list of funded medications.

More people can access the drug rituximab, which is used to treat some kinds of lymphomas. Breast cancer drug docetaxel has also been made more widely available and access to funded treatment for Crohn's disease, Cystic fibrosis and asthma were widened.

The Government's drug-buying agency yesterday released its annual report for the year ending June 30, which showed 14 new medicines were funded in the past year and access to 10 others was widened.

An extra 56,840 patients were expected to benefit from the changes, on top of the record 3.3 million New Zealanders who received fully funded medication in the past year.

Pharmac stayed within its $777.4m budget in a year which saw it take on additional roles, including managing the national immunisation schedule and hospital medicines and medical devices.

It also contributed $379,000 towards a research trial in Finland looking at whether the nine week or 12-month duration of breast cancer drug Herceptin offers a better treatment.

Ad Feedback

- The Dominion Post

Special offers
Opinion poll

Where do you stand on political coat-tail riding?

If it gets marginalised voices into Parliament, I'm for it.

I'm against it - if you don't get the votes, you shouldn't be there.

It's just part of the political game.

Vote Result

Related story: Voters reject riding on the coat-tails

Featured Promotions

Sponsored Content